Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treatment and/or prevention of cancer

A composition and drug technology, applied in the direction of drug combination, medical preparations containing active ingredients, antineoplastic drugs, etc.

Active Publication Date: 2012-12-12
TORAY IND INC
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition, based on the report of Non-Patent Document 10, which considers CAPRIN-1 to be a cell membrane protein, Patent Documents 2 and 3 describe that CAPRIN-1, as a cell membrane protein, can be used as a target of antibody drugs for cancer treatment under the name of M11S1 ( In the examples, there is no description about the treatment using the antibody against this protein at all)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treatment and/or prevention of cancer
  • Pharmaceutical composition for treatment and/or prevention of cancer
  • Pharmaceutical composition for treatment and/or prevention of cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0056] The preparation of the antigen, the preparation of the antibody, and the pharmaceutical composition related to the present invention will be described below.

[0057]

[0058] The protein or fragment thereof used as the sensitizing antigen for obtaining the antibody against CAPRIN-1 used in the present invention may be derived from humans, dogs, cows, horses, mice, rats, chickens, etc., and may be the source thereof There are no restrictions on the types of animals. However, it is preferable to select the protein or fragments thereof in consideration of suitability with the parent cell used for cell fusion. Generally, mammalian-derived proteins are preferred, and human-derived proteins are particularly preferred. For example, when CAPRIN-1 is human CAPRIN-1, human CAPRIN-1 protein and / or partial peptides thereof, cells expressing human CAPRIN-1, etc. can be used.

[0059] The base sequence and amino acid sequence of human CAPRIN-1 and its homologues can be accessed, for exa...

Embodiment 1

[0196] Example 1 Identification of a new cancer antigen protein using the SEREX method

[0197] (1) Preparation of cDNA library

[0198] Total RNA was extracted from the testis tissue of healthy dogs by the Acid guanidium-Phenol-Chloroform method (Acid guanidium-Phenol-Chloroform method), and the Oligotex-dT30 mRNA purification kit (manufactured by Takara Shuzo Co., Ltd.) was used to purify it according to the instructions attached to the kit. Poly A RNA.

[0199] The mRNA (5 μg) thus obtained was used to synthesize a dog testis cDNA phage library. CDNA synthesis kit, ZAP-cDNA synthesis kit, and ZAP-cDNA Gigapack III Gold Cloning kit (manufactured by STRATAGENE) were used to prepare the cDNA phage library, and the library was prepared according to the instructions attached to the kit. The size of the prepared cDNA phage library is 7.73×10 5 pfu / ml.

[0200] (2) Screening of cDNA library using serum

[0201] The dog testis cDNA phage library prepared above was used for immunoscreening...

Embodiment 2

[0223] Example 2 Preparation of new human cancer antigen protein

[0224] (1) Preparation of recombinant protein

[0225] Based on the gene of SEQ ID NO: 1 obtained in Example 1, a recombinant protein of a human homologous gene was prepared by the following method. PCR was performed as follows: 1 μl of expressed cDNA can be confirmed by RT-PCR using the cDNA of various tissues and cells prepared in Example 1, and two primers containing SacI and XhoI restriction enzyme cleavage sequences (SEQ ID Nos. 38 and 39) Description) 0.4μM, 0.2mM dNTP, 1.25U PrimeSTAR HS polymerase (manufactured by Takara Shuzo Co., Ltd.)), each reagent and attached buffer are added to make the total amount 50 μl, using Thermal Cycler (manufactured by BIO RAD), The cycle of 98°C for 10 seconds and 68°C for 2.5 minutes was repeated 30 times. In addition, the above-mentioned two kinds of primers are primers that amplify the region encoding the full length of the amino acid sequence of sequence number 2. Afte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention identifies a cancer antigen protein which is expressed specifically on the surface of a cancer cell, and provides a use of an antibody, which targets the cancer antigen protein, as a therapeutic and / or prophylactic agent for cancer. Specifically disclosed is a pharmaceutical composition for the treatment and / or prevention of cancer, which is characterized by containing, as an active ingredient, an antibody that is immunologically reactive with a partial polypeptide of CAPRIN-1 represented by the even-numbered sequences of SEQ ID NOS: 2-30, said partial polypeptide comprising the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, or a fragment of the antibody.

Description

Technical field [0001] The present invention relates to new medical uses of antibodies against CAPRIN-1 or fragments thereof as therapeutic and / or preventive agents for cancer. Background technique [0002] Cancer is the number one cause of death. The current treatment is based on surgery, combined with radiotherapy and chemotherapy. Although there have been the development of new surgical methods and the discovery of new anti-cancer drugs in recent years, the current situation is that except for some cancers, the results of cancer treatment have not improved much. In recent years, with the progress of molecular biology and cancer immunology, antibodies that specifically react with cancer, cancer antigens recognized by cytotoxic T cells, and genes encoding cancer antigens have been identified. Expectations for targeted specific cancer treatment methods are increasing (Non-Patent Document 1). [0003] In cancer treatment methods, in order to reduce side effects, it is expected tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61P35/02C07K16/30
CPCA61K2039/505C07K16/3015C07K16/3053A61P35/00A61P35/02C07K2317/34A61K39/39558C07K16/30
Inventor 冈野文义斋藤孝则小林真一井户隆喜成田义规
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com